Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone.

abstract：:Paclitaxel and docetaxel are excellent agents with a high antitumor effect for the treatment of previously anthracycline-exposed metastatic breast cancer. There has been no standard treatment for patients who undergo therapy of a taxan-resistant metastatic breast cancer. Paclitaxel has partial non-cross-resistance in ...

journal_title：Anti-cancer drugs

authors： Suzuma T,Sakurai T,Yoshimura G,Umemura T,Tamaki T,Naito Y

更新日期：2000-08-01 00:00:00

abstract：:Patients with advanced gastric cancer unresponsive or progressing after PELF chemotherapy (5-fluorouracil, leucovorin, cisplatin and epidoxorubicin) received paclitaxel at the dose of 225 mg/m2 every 3 weeks, over 3 h infusion. Thirty-six patients entered the study, and all of them were evaluable for response and toxi...

journal_title：Anti-cancer drugs

authors： Cascinu S,Graziano F,Cardarelli N,Marcellini M,Giordani P,Menichetti ET,Catalano G

更新日期：1998-04-01 00:00:00

abstract：:Previously, we synthesized a series of hydrazide class of compounds and examined their cytotoxicity in a number of cancer cell lines. Among these analogues, SC144 exhibited potent cytotoxicity against a panel of drug-sensitive and drug-resistant cancer cell lines. To further explore its therapeutic potentials in the c...

journal_title：Anti-cancer drugs

authors： Oshima T,Cao X,Grande F,Yamada R,Garofalo A,Louie S,Neamati N

更新日期：2009-06-01 00:00:00

abstract：:C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the overall prognostic impact of CRP in patients with metastatic RCC treated with sorafenib. Between April 2008 and December 2014, 40 consecutive patients with metastatic RCC wer...

journal_title：Anti-cancer drugs

authors： Fujita T,Nishi M,Tabata K,Matsumoto K,Yoshida K,Iwamura M

更新日期：2016-11-01 00:00:00

abstract：:Pancreatic and biliary tract carcinomas are very chemoresistant. After a first-line treatment with a gemcitabine-based regimen, no second-line scheme is consolidated in clinical practice. The aim of this study was to evaluate the toxicity and the activity of the FOLFIRI regimen as first-line or second-line chemotherap...

journal_title：Anti-cancer drugs

authors： Moretto R,Raimondo L,De Stefano A,Cella CA,Matano E,De Placido S,Carlomagno C

更新日期：2013-10-01 00:00:00

abstract：:Epirubicin is usually administered in combination with other cytotoxics. Few pharmacological studies address whether relevant clinical interactions occur in vitro between these drugs. This study investigated whether epirubicin interacted with other cytotoxics or anti-emetics. The following drugs were prepared at pharm...

journal_title：Anti-cancer drugs

authors： Zhang W,Zalcberg JR,Cosolo W

更新日期：1992-12-01 00:00:00

abstract：:Docetaxel has shown promise for the treatment of hormone-refractory prostate cancer and has become the standard of care. The flare phenomenon is a known entity in androgen-deprivation therapy of advanced prostate cancer and it has also been described in palliative chemotherapy of hormone-refractory prostate cancer. Th...

journal_title：Anti-cancer drugs

authors： Olbert PJ,Hegele A,Kraeuter P,Heidenreich A,Hofmann R,Schrader AJ

更新日期：2006-09-01 00:00:00

abstract：:The aim of this study was to evaluate the efficacy and tolerability of the combination of paclitaxel and nedaplatin in patients with advanced esophageal cancer. Patients (n = 310) with recurrent or metastatic esophageal squamous cell carcinoma, who had a maximum of one previous chemotherapy regimen, were enrolled in t...

journal_title：Anti-cancer drugs

authors： Du J,Hu C,Zhang Y,Hu B,Wang F,Zhang Y

更新日期：2015-01-01 00:00:00

abstract：:Topical treatment of skin metastases with a cytotoxic agent is attractive for its easy self-administration and absence of major systemic interference. Miltefosine exerts its cytotoxicity by acting on cell membrane phospholipids and can be administered topically. Twenty breast cancer patients with progression of skin m...

journal_title：Anti-cancer drugs

authors： Smorenburg CH,Seynaeve C,Bontenbal M,Planting AS,Sindermann H,Verweij J

更新日期：2000-11-01 00:00:00

abstract：:Interleukin-12 (IL-12) has important immunomodulatory effects on T and natural killer (NK) cells that might be exploited in anticancer treatment. Murine IL-12 models have shown antimetastatic and antitumor effects against murine tumors in vivo. Data on the effects of human IL-12 on human tumors are confined to 51Cr-re...

journal_title：Anti-cancer drugs

authors： Izquierdo MA,Degen D,Sypek JP,Von Hoff DD

更新日期：1996-05-01 00:00:00

abstract：:The tetracycline family includes tetracycline, doxycycline and minocycline, all of which have been used as antibiotics effectively for decades. New uses emerged for these compounds after their effect on mitochondrial function was discovered. Cytostatic and cytotoxic activity of these compounds was shown against cell l...

journal_title：Anti-cancer drugs

authors： Saikali Z,Singh G

更新日期：2003-11-01 00:00:00

abstract：:Lipoplatin, currently under phase III evaluation, is a novel liposomal cisplatin formulation highly effective against cancers. Lipoplatin has eliminated or reduced the systemic toxicity frequently seen for cisplatin. The objective of the present study was to determine whether the cytotoxic effect of lipoplatin is depe...

journal_title：Anti-cancer drugs

authors： Fedier A,Poyet C,Perucchini D,Boulikas T,Fink D

更新日期：2006-03-01 00:00:00

abstract：:Thioredoxin (Trx) expression is increased in several human primary cancers associated with aggressive tumor growth and decreased patient survival, and the Trx/Trx reductase (TrxR) system therefore provides an attractive target for cancer drug development. Various gold(III) compounds with none, one, two or three carbon...

journal_title：Anti-cancer drugs

authors： Engman L,McNaughton M,Gajewska M,Kumar S,Birmingham A,Powis G

更新日期：2006-06-01 00:00:00

abstract：:This study was performed to evaluate the role of protein kinase C (PKC) activity in the development of chemoresistance in clinical breast cancer cells. To simulate the clinical situation, native tumor cells derived from 10 patients with advanced breast cancer were brought into short-term cultures, and treated with ant...

journal_title：Anti-cancer drugs

authors： Schöndorf T,Hoopmann M,Breidenbach M,Rein DT,Göhring UJ,Becker M,Mallmann P,Kurbacher CM

更新日期：2004-03-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) is the world's leading cause of cancer death and about 75% of all patients have advanced disease incurable with localized treatments (surgery and radiotherapy) alone. The aims of therapy in these are palliation of symptoms and extension of life. A substantial body of evidence has eme...

journal_title：Anti-cancer drugs

authors： Nicum S,Cullen MH

更新日期：2000-09-01 00:00:00

abstract：:E7070 is a novel sulfonamide anticancer agent that arrests the G(1)/S phase of the cell cycle. Preclinical and phase I studies have demonstrated non-linear pharmacokinetics (PK) of the drug. A population PK analysis revealed that the human plasma concentration-time data were best described by a three-compartment model...

journal_title：Anti-cancer drugs

authors： Bongard HJ,Pluim D,Waardenburg RC,Ravic M,Beijnen JH,Schellens JH

更新日期：2003-07-01 00:00:00

abstract：:Urothelial carcinoma of the bladder accounts for over 95% of bladder tumours in France. The incidence of this disease is increasing in industrialised countries. Several types of bladder cancer can be distinguished: (1) superficial tumours which have a risk of recurrence and progression, although conservative treatment...

journal_title：Anti-cancer drugs

authors： Rischmann P

更新日期：2000-10-01 00:00:00

abstract：:There is growing interest in the discovery of bioactive metabolites from endophytes as an alternative source of therapeutics. Identification of their therapeutic targets is essential in understanding the underlying mechanisms and enhancing the resultant therapeutic effects. As such, bioactive compounds produced by end...

journal_title：Anti-cancer drugs

authors： Hazalin NA,Lim SM,Cole AL,Majeed AB,Ramasamy K

更新日期：2013-09-01 00:00:00

abstract：:(E)-2'-deoxy-2'-(fluoromethylene) cytidine (MDL101,731) is a new deoxycytidine analog which shows potent antitumor activity against several human tumor models. We previously showed that MDL101,731 inhibited human ribonucleotide reductase (RNR) in HeLa S3 human cervical carcinoma cells. Recently, it has been reported t...

journal_title：Anti-cancer drugs

authors： Kanazawa J,Takahashi T,Akinaga S,Tamaoki T,Okabe M

更新日期：1998-08-01 00:00:00

abstract：:Four novel 4-substituted 5-nitrophthalimides (5-substituted-6-nitro-1,3-dihydro-isoindol-1,3-diones), 6, 7, 10 and 11, and the known 5 are prepared as analogs of the dinitrobenzamide prodrug CB 1954, 1, and considered as potential candidates for gene-directed enzyme prodrug therapy. All the phthalimides are poor subst...

journal_title：Anti-cancer drugs

authors： Mehta LK,Hobbs S,Chen S,Knox RJ,Parrick J

更新日期：1999-09-01 00:00:00

abstract：:Docetaxel is a new antimicrotubule agent that induces a predominantly sensory neuropathy that is mild in most patients. This prospective study was performed to determine if corticosteroid co-medication reduces the incidence and severity of docetaxel-induced neuropathy. Two groups of patients treated with docetaxel in ...

journal_title：Anti-cancer drugs

authors： Pronk LC,Hilkens PH,van den Bent MJ,van Putten WL,Stoter G,Verweij J

更新日期：1998-10-01 00:00:00

abstract：:Caffeic acid phenethyl ester (CAPE) is a major propolis component that possesses a variety of pharmacological properties such as antioxidant and anticancer effects. Herein, we investigated the effectiveness of CAPE on cytotoxicity of clinically used anticancer drugs, doxorubicin (DXR) and cisplatin (CDDP), in parental...

journal_title：Anti-cancer drugs

authors： Matsunaga T,Tsuchimura S,Azuma N,Endo S,Ichihara K,Ikari A

更新日期：2019-03-01 00:00:00

abstract：:The sea, covering 70% of the Earth's surface, offers a considerably broader spectrum of biological diversity than terra firma. Containing approximately 75% of all living organisms, the marine environment offers a rich source of natural products with potential therapeutic application. Marine organisms have evolved the ...

journal_title：Anti-cancer drugs

authors： Jimeno JM

更新日期：2002-05-01 00:00:00

abstract：:Adrenocortical tumor (ACT) is a malignancy with a low incidence rate and the current therapy for advanced disease has a limited impact on overall patient survival. A previous study from our group suggested that elevated expression of aurora-A and aurora-B is associated with poor outcome in childhood ACT. Similar resul...

journal_title：Anti-cancer drugs

authors： Borges KS,Andrade AF,Silveira VS,Marco Antonio DS,Vasconcelos EJR,Antonini SRR,Tone LG,Scrideli CA

更新日期：2017-07-01 00:00:00

abstract：:This study assessed the clinical activity and safety of twice-weekly paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin (TP-HDFL) in patients with recurrent or metastatic esophageal squamous cell carcinoma. The regimen, composed of paclitaxel 35 mg/m 1-h intravenous infusion on days 1, 4, 8 and 11; c...

journal_title：Anti-cancer drugs

authors： Lin CC,Yeh KH,Yang CH,Hsu C,Tsai YC,Hsu WL,Cheng AL,Hsu CH

更新日期：2007-07-01 00:00:00

abstract：:Paeonol, a major phenolic component of Moutan Cortex, is known to have antitumor effects through an unknown mechanism. In this study, we tried to elucidate the anticancer effects of paeonol on human hepatocellular carcinoma (HCC) cell lines BEL-7404, SMMC-7721, and MHCC97-H in vitro. Using the 3-[4,5-dimethylthiazol-2...

journal_title：Anti-cancer drugs

authors： Chunhu Z,Suiyu H,Meiqun C,Guilin X,Yunhui L

更新日期：2008-04-01 00:00:00

abstract：:Patients with metastatic squamous cell cancer of the head and neck (SCCHN) have a poor prognosis, with most patients surviving less than a year. Immunotherapy (IO) is changing the natural history of the disease and programmed death-ligand 1 (PD-L1) inhibitors are showing notable improvements in survival with a more fa...

journal_title：Anti-cancer drugs

authors： Cabezas-Camarero S,Cabrera-Martín MN,Pérez-Segura P

更新日期：2019-02-01 00:00:00

abstract：:Topoisomerase IIα is a nuclear enzyme that alters DNA topology. It is a well-known anticancer target and related to cell differentiation status. All-trans retinoic acid (ATRA), an important active metabolite of vitamin A, is a promising anticancer agent in numerous malignancies. However, there are little data on the e...

journal_title：Anti-cancer drugs

authors： Li X,Li Y,Shen X,Fu S,Han S,Feng Q

更新日期：2015-08-01 00:00:00

abstract：:Intensive cisplatin and oral etoposide for relapsed epithelial ovarian cancer (EOC), commonly known as the van der Burg (VDB) protocol, has been reported to improve response rates and progression-free survival. We report on all patients with relapsed EOC treated on the VDB protocol at the Cambridge Gynae-Oncology Cent...

journal_title：Anti-cancer drugs

authors： Gounaris I,Iddawela M,Parkinson C,Pratt J,Hatcher H,Basu B,Tan LT,Brenton JD,Earl HM

更新日期：2016-03-01 00:00:00

abstract：:We carried out a detailed comparative study of the pharmacokinetics and toxicity of methotrexate (MTX) and 7-hydroxy-methotrexate (7-OH-MTX) after high-dose intravenous methotrexate (HD-MTX) in children with acute lymphoblastic leukemia (ALL). Overall, 65 children were treated with 5 g/m2/24 h MTX and 88 children were...

journal_title：Anti-cancer drugs

authors： Csordas K,Hegyi M,Eipel OT,Muller J,Erdelyi DJ,Kovacs GT

更新日期：2013-02-01 00:00:00